Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Development for anthrax and MRSA treatment
Compound found with ability to kill problem bacteria

The discovery of a new chemical compound produced by a microorganism has offered hope for the future treatment of anthrax and methicillin-resistant staphylococcus aureus (MRSA).

A scientist from the Scripps Institution of Oceanology at the University of California, San Diego, first collected the microorganism in 2012, from sediments close to the Santa Barbara shore.

Following the finding, a San Diego-based company worked in conjunction with the team from the university's Center for Marine Biotechnology and Biomedicine, to decipher the unusual structure of the compound's molecules.

The team then discovered that the unusual compound, which they named anthracimycin, has the power to kill bacteria that causes anthrax and MRSA.

As a result, it is hoped that the finding will one day lead to the development of a new antibiotic drug.

"The real importance if this work is the fact that anthracimycin has a new and unique chemical structure," said William Fenical, professor of oceanography and pharmaceutical science, who led the team.

"The discovery of truly new antibiotic compounds is compounds is quite rare. This discovery adds to many previous discoveries, which show that marine bacteria are genetically and chemically unique."

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.